US biotechnology company IMUNON, Inc. (NASDAQ: IMNN) on Wednesday presented positive translational findings for its gene-based interleukin-12 (IL-12) immunotherapy, IMNN-001, from its Phase 2 OVATION 2 Study.

The study evaluated 112 participants with newly-diagnosed, advanced ovarian cancer treated with IMNN-001 alongside standard neoadjuvant and adjuvant chemotherapy.

The study demonstrated a 27-fold increase in interleukin-12 (IL-12), a 62-fold rise in interferon-gamma (IFN-γ), and a 36-fold increase in tumour necrosis factor-alpha (TNF-α) levels within the tumour microenvironment. These results highlight the therapy's tumour-targeted effect and favourable safety profile.

These translational results align with previous overall survival data, where IMNN-001 used in conjunction with chemotherapy showed meaningful improvements in survival and response outcomes. IMNN-001 utilises Imunon's proprietary TheraPlas platform, enabling localised IL-12 secretion to combat peritoneal tumours effectively while minimising systemic exposure.

The therapy aims to address epithelial ovarian cancer, a malignancy impacting approximately 20,000 women annually in the United States, with advanced-stage survival rates remaining alarmingly low.

IMUNON has initiated its Phase 3 OVATION 3 trial, which aims to confirm IMNN-001's clinical benefit in improving survival and reducing recurrence in this high-risk patient population. The first two clinical sites launched in May 2025.